428 related articles for article (PubMed ID: 30970204)
1. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
2. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
3. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
5. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
6. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
7. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Tom WL; Van Syoc M; Chanda S; Zane LT
Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
10. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
[TBL] [Abstract][Full Text] [Related]
11. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
14. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
15. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
Stein Gold LF; Takiya L; Zang C; Sanders P; Feldman SR
J Drugs Dermatol; 2020 Jun; 19(6):619-624. PubMed ID: 32574023
[TBL] [Abstract][Full Text] [Related]
16. Topical Agents for the Treatment of Atopic Dermatitis.
Eichenfield LF; Luger T; Papp K; Silverberg JI; Sierka D; Zang C; Tallman AM; Zielinski MA; Ports WC
J Drugs Dermatol; 2020 Jan; 19(1):50-64. PubMed ID: 31985912
[TBL] [Abstract][Full Text] [Related]
17. Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Draelos ZD; Stein Gold LF; Murrell DF; Hughes MH; Zane LT
J Drugs Dermatol; 2016 Feb; 15(2):172-6. PubMed ID: 26885784
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
[TBL] [Abstract][Full Text] [Related]
19. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
20. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
